Drug Trial Radar · NCT05144243
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
44
Actual
Start
Jan 6, 2022
Primary completion
Mar 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Genentech, Inc.
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how safe the combination of azacitidine and venetoclax is and how effective the combination of azacitidine and venetoclax is in adult participants with acute myeloid leukemia (AML), in China. Adverse events and change in disease state will be assessed. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing doses of venetoclax. Adult participants with a diagnosis of AML will be enrolled. Around 40 participants will be enrolled in the study in approximately 30 sites in China. At cycle 1 during ramp-up period, participants will receive venetoclax oral tablets once daily in increasing doses until the study dose is achieved on day 3. Then ventoclax oral tablets will continue once daily thereafter. Azacitidine will be given by subcutaneous injection (SC) for 7 days beginning on Day 1 of each 28-day cycle. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
VenetoclaxDrug
Tablet: Oral
AzacitidineDrug
Subcutaneous Injection (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Approximately 19 Months
- Number of Laboratory Abnormalities from Clinical Laboratory Values (Hematology and Chemistry)Time frame: Up to Approximately 19 Months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Duplicate_The Affiliated Hospital of Guizhou Medical University /ID# 232465
Guiyang, China
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 233179
Beijing, Beijing Municipality, China
Peking University International Hospital /ID# 232254
Beijing, Beijing Municipality, China
Sun Yat-Sen University Cancer Center /ID# 231793
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University /ID# 231792
Guangzhou, Guangdong, China
Guangdong Second Provincial General Hospital /ID# 232059
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University /ID# 231938
Guangzhou, Guangdong, China
Shenzhen Second People's Hospital /ID# 231444
Shenzhen, Guangdong, China
People's Hospital of Henan Province /ID# 232568
Zhengzhou, Henan, China
Henan Cancer Hospital /ID# 231940
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233178
Wuhan, Hubei, China
Xiangyang Central Hospital /ID# 232452
Xiangyang, Hubei, China
The First Affiliated Hospital of Soochow University /ID# 232418
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University /ID# 231442
Nanchang, Jiangxi, China
Qinghai University Affiliated Hospital /ID# 232419
Xining, Qinghai, China
The Second People's Hospital of Yibin /ID# 233180
Yibin, Sichuan, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 232253
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Wenzhou Medical University /ID# 233704
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.